Sugi Predict

Sugi Predict / Compounds / SCHEMBL30510342

SCHEMBL30510342

SCHEMBL30510342

COCC[C@@H](C(=O)O)N(C(=O)OC)C1c2ccccc2-c2ccccc21

nearest known ligand 0.38

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
▸ CYP1A2 P05177 1/20 0.36
▸ TSHR P16473 1/20 0.36
▸ MAPK1 P28482 1/20 0.36
▸ KDM4E B2RXH2 4/20 0.36
▸ GAA P10253 2/20 0.35
▸ HPGD P15428 2/20 0.35
▸ L3MBTL1 Q9Y468 1/20 0.34
▸ GPR3 P46089 1/20 0.34
▸ KMT2A Q03164 1/20 0.34
▸ POLB P06746 1/20 0.33
▸ PPARG P37231 1/20 0.33
▸ PPARA Q07869 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14648233 1.00 CYP1A2 (0.36) CYP1A2TSHRMAPK1KDM4EGAA
SCHEMBL1064350 0.90 GAA (0.35) CYP1A2TSHRMAPK1KDM4EGAA
SCHEMBL8812896 0.90 CYP1A2 (0.38) CYP1A2TSHRMAPK1KDM4EGAA
SCHEMBL30510335 0.90 CYP1A2 (0.38) CYP1A2TSHRMAPK1KDM4EGAA
SCHEMBL25177898 0.89 CYP1A2 (0.37) CYP1A2TSHRGAAL3MBTL1GPR3
SCHEMBL8892535 0.89 CYP1A2 (0.37) CYP1A2TSHRGAAGPR3KMT2A
SCHEMBL8893033 0.89 CYP1A2 (0.37) CYP1A2TSHRGAAGPR3KMT2A
SCHEMBL16933112 0.88 CYP1A2 (0.39) CYP1A2TSHRMAPK1KDM4EHPGD
SCHEMBL28486576 0.88 CYP1A2 (0.36) CYP1A2TSHRKDM4EGAAHPGD
SCHEMBL25178735 0.88 CYP1A2 (0.36) CYP1A2TSHRMAPK1KDM4EGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12371454-B2 Cyclic peptide compound having Kras inhibitory action CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2025-07-29 — — US disclosed
US-20240400617-A1 CYCLIC PEPTIDE COMPOUND HAVING KRAS INHIBITORY ACTION CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2024-12-05 — — US disclosed
US-20240148821-A1 PHARMACEUTICAL USE OF CYCLIC PEPTIDE COMPOUND CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2024-05-09 — — US disclosed
EP-4316503-A1 PHARMACEUTICAL USE OF CYCLIC PEPTIDE COMPOUND CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2024-02-07 — — EP disclosed
US-20230151060-A1 CYCLIC PEPTIDE COMPOUND HAVING KRAS INHIBITORY ACTION CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2023-05-18 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230151060-A1 CYCLIC PEPTIDE COMPOUND HAVING KRAS INHIBITORY ACTION KRAS, NRAS, HRAS CYP1A2 4845/4885TSHR 3295/4885MAPK1 165/4885
US-20240400617-A1 CYCLIC PEPTIDE COMPOUND HAVING KRAS INHIBITORY ACTION KRAS, NRAS, HRAS CYP1A2 4845/4885TSHR 3295/4885MAPK1 165/4885
US-20240148821-A1 PHARMACEUTICAL USE OF CYCLIC PEPTIDE COMPOUND VIP, IAPP, KRAS CYP1A2 4648/4885TSHR 1619/4885MAPK1 812/4885
US-12371454-B2 Cyclic peptide compound having Kras inhibitory action KRAS, NRAS, HRAS CYP1A2 4845/4885TSHR 3295/4885MAPK1 165/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.